Fig. 4.

Abrogation of CD47 signaling enhances in vivo adaptive immune response to Triple Negative Breast Cancer cell lines in multiple mouse strains. a In vivo analysis of WT C57Bl/6 mice engrafted with 2 × 10⁶ EO771 cells with CD47 shRNA KD, a scrambled shRNA control, or CD47 overexpression (OE). b and c In vivo analysis of WT Balb/c mice engrafted with 5 × 10⁵ JC cells with CD47 KD and 10⁴ 4T1 cells with CD47 KD, respectively. d Representative in vivo analysis of C57Bl/6 mice engrafted with 10⁶ EO771-WT cells treated with PBS or the anti-CD47 antibody VX-1000R. N = 10 mice per group for a and d. N = 5 mice per group for b and c. Each panel is a representative survival and growth kinetics analysis (panel insert) from one animal study and was repeated at least once with equivalent results. The dotted lines and circle markers indicate mice engrafted with cells expressing the shScramble; solid lines and square markers represent those mice engrafted with cells with CD47 shRNA knockdown; dashed lines and triangle markers indicate mice engrafted with cells with CD47 overexpression